ADC Therapeutics SA — Form 6-K Summary
Reporting period: September 2022; furnished September 21, 2022. The filing announces abstracts and planned presentations for the Society of Hematologic Oncology annual meeting (SOHO 2022), scheduled for September 28–October 1, 2022.
Business Context
ADC Therapeutics is a commercial-stage biotechnology company developing antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Its marketed product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved by the FDA for adults with relapsed or refractory large B-cell lymphoma after two or more systemic therapies. Camidanlumab tesirine (Cami), a CD25-directed ADC, remains investigational.
Clinical and Other Key Metrics
- LOTIS-5 Phase 3 safety run-in: 20 patients with relapsed or refractory diffuse large B-cell lymphoma were enrolled.
- Data cutoff: February 28, 2022.
- Overall response rate: 15 of 20 patients, or 75%, by central review.
- Complete response rate: 8 of 20 patients, or 40%.
- Partial response rate: 7 of 20 patients, or 35%.
- Common all-grade treatment-emergent adverse events: rash, 25%; fatigue, 20%; and increased gamma-glutamyl transferase, 20%.
- Most common grade 3 or higher adverse events: increased gamma-glutamyl transferase, 15%; increased alanine aminotransferase, 10%; and neutropenia, 10%.
- Part 2 of LOTIS-5 is expected to randomize approximately 330 patients 1:1 between Lonca-R and the R-GemOx control regimen.
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other corporate financial metrics.
Material Changes Versus the Prior Comparable Period
The filing does not present period-over-period financial results or identify a material financial change. It reports initial safety run-in results for LOTIS-5 and confirms upcoming SOHO 2022 presentations, including updated Cami data and additional ZYNLONTA analyses.
Outlook, Risks, and Unusual Items
- ZYNLONTA’s FDA approval is under the accelerated approval pathway. Continued approval may depend on verification and description of clinical benefit in a confirmatory trial.
- The LOTIS-5 results are based on a small, nonrandomized 20-patient safety run-in and may not predict results from the randomized portion of the study.
- The reported data are preliminary clinical findings with a February 28, 2022 cutoff; the filing does not provide statistical significance, duration of response, progression-free survival, overall survival, or full follow-up.
- Cami is being evaluated in a pivotal Phase 2 Hodgkin lymphoma trial and a Phase 1b trial in solid tumors, but this filing does not report updated efficacy results from those studies.
- The filing identifies no new safety signals in the LOTIS-5 safety run-in, while reporting treatment-emergent adverse events including liver-enzyme elevations, rash, fatigue, and neutropenia.
Investor Verification Points
- Verify subsequent randomized LOTIS-5 efficacy, safety, enrollment, and statistical results.
- Verify confirmatory-trial progress supporting ZYNLONTA’s accelerated approval.
- Review updated Cami efficacy, durability, and safety data from the pivotal Phase 2 study.
- Assess the company’s separately filed financial statements for cash runway, liquidity, debt, operating losses, and commercialization expenses, which are not included in this 6-K.
- Confirm whether the reported response rates and adverse-event frequencies change with longer follow-up or a larger patient population.